1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsDPA26BZ03-DV014: Real-Time Pathogen-Host Interactome Prediction is sponsored by DARPA (Defense Advanced Research Projects Agency). This SBIR topic seeks to develop and demonstrate a capability to rapidly characterize host–pathogen interactions from pathogen protein sequence alone, enabling timely medical countermeasure prioritization and force health protection against novel or emerging biological threats.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Real-Time Pathogen-Host Interactome Prediction: SBIR | DARPA Department of War organization.
Real-Time Pathogen-Host Interactome Prediction: SBIR Real-Time Pathogen-Host Interactome Prediction: SBIR Partner with Us to Accelerate DARPA Innovation OUSD (R&E) critical technology area(s) : Biotechnology Objective: Develop and demonstrate a capability to rapidly characterize host–pathogen interactions from pathogen protein sequence alone, enabling timely medical countermeasure prioritization and force health protection against novel or emerging biological threats.
Description: When novel or emerging pathogens (bacteria, viruses, parasites) are encountered, characterization of their interactions with human hosts currently requires weeks to months of experimental work, often yielding incomplete understanding. This capability gap limits rapid therapeutic response and countermeasure development.
Recent advances in protein language models and large-scale protein-protein interaction (PPI) prediction make computational threat characterization feasible. This topic seeks to develop and validate an operationally deployable capability that can characterize any pathogen—naturally emerging, accidentally released, or engineered—from protein sequence data alone.
The system must: (1) predict host-pathogen protein interactions with high accuracy across viral, bacterial, and parasitic pathogen classes; (2) demonstrate zero-shot prediction capability on previously unseen pathogens; (3) provide comprehensive functional annotation of both pathogen and host proteins; (4) generate ranked mechanistic hypotheses about infection pathways through automated analysis; and (5) complete core predictions within 15 minutes and full characterization reports within one hour on standard computing hardware.
Proposers must demonstrate rigorous evaluation methods to ensure the system generalizes to unseen pathogens rather than memorizing training data. Performance must be benchmarked against established protein interaction databases and validated experimentally using standard binding assay techniques.
The end-state capability enables rapid biological threat characterization to support medical countermeasure prioritization and force health protection. This topic is soliciting Direct to Phase II proposals only. Feasibility Requirements: Proposers must demonstrate that Phase I feasibility has been achieved through prior work.
Required documentation includes: Benchmark Performance Data: Quantified PPI prediction results on at least one pathogen class with rigorous data separation methods Zero-Shot Validation: Demonstrated recovery of known host-pathogen interactions without training on that specific pathogen system Pipeline Demonstration: At least one complete end-to-end run from pathogen sequence input to mechanistic characterization report meeting timing requirements Functional Annotation Capability: Operational tools for protein functional prediction including gene ontology terms, subcellular localization, and pathway enrichment analysis DP2 Base Period (9 months): Scale and validate the computational pipeline across expanded pathogen coverage including higher-consequence agents.
Deliver comprehensive experimental validation of novel predicted interactions. DP2 Option Period (9 months): Complete transition-ready software delivery with full documentation, demonstrate drug repurposing capability, and provide final performance characterization across the full threat spectrum.
Phase II represents a major research and development effort that scales the validated Phase I pipeline into a deployable threat-characterization capability, with comprehensive experimental validation, druggability and drug-repurposing demonstration, and extension to higher-consequence pathogens.
The Phase II effort culminates in a well-defined deliverable prototype — an end-to-end software pipeline and accompanying validation dataset — that can be transitioned to an operational user.
Phase II fixed payable milestones for this program should include: Month 2: Updated system architecture report and expanded pathogen coverage plan Month 4: Evaluation dataset acquisition report covering higher-consequence pathogens and biological toxins Month 6: Interim performance report with comprehensive benchmarking results Month 9: Base period final report with experimental validation of =25 novel interactions (=30% hit rate) and drug repurposing demonstration Month 12: Live demonstration to DARPA with prospective characterization run on Government-selected pathogen Month 15: Final software delivery with source code and documentation Month 18: Final report with transition plan and performance characterization Phase III dual use applications Military Applications: Biosurveillance and rapid threat characterization, medical countermeasure prioritization, force health protection for deployed personnel, and intelligence analysis support.
Commercial Applications: Drug discovery and repurposing, vaccine target identification, diagnostic biomarker development, veterinary and agricultural biosecurity, and integration with existing bioinformatics platforms. [1] Hallee, L. et al.
"Protein-Protein Interaction Prediction is Achievable with Large Language Models”. bioRxiv 2023. 06.
07. 544109; doi: https://doi. org/10.
1101/2023. 06. 07.
544109 [2] Gleghorn, J. P. et al.
University of Delaware, Biomedical Engineering — host-pathogen biophysical characterization publications. [3] Park, Y. , Marcotte, E.
M. "Flaws in evaluation schemes for pair-input computational predictions" (C3 data stratification standard for PPI evaluation), Nature Methods, 2012. [4] Evans, R.
et al. "Protein complex prediction with AlphaFold-Multimer," bioRxiv, 2022 (structural baseline for benchmarking). [5] PHI-base (pathogen-host interactions database); VirHostNet; HPIDB; IntAct.
[6] Gordon, D. E. et al.
"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing," Nature, 2020 (reference interactome for zero-shot validation). [7] Reactome, KEGG, Gene Ontology Consortium — pathway enrichment reference databases.
Host-pathogen interaction, protein-protein interaction prediction, protein language model, biological threat characterization, computational biology, drug repurposing, biodefense For additional information and to submit your full proposal package, visit the DSIP Portal . Publication: June 3, 2026 Closes: July 22, 2026 12:00 PM ET DoW SBIR 2026 BAA | Release 3
According to the current listing, eligibility includes: Small business concerns (SBCs). Confirm the full requirements in the official notice before applying.
DPA26BZ03-DV014: Real-Time Pathogen-Host Interactome Prediction is funded by DARPA (Defense Advanced Research Projects Agency). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Quantum Benchmarking Initiative (QBI) is sponsored by DARPA (Defense Advanced Research Projects Agency). The Quantum Benchmarking Initiative (QBI) aims to determine whether it's possible to build a utility-scale quantum computer by 2033. It solicits research proposals in quantum benchmarking and is structured in three stages: concept description, R&D plan, and validation/co-design.
Photonic Integrated Circuit Architectures for Scalable System Objectives (PICASSO) is sponsored by DARPA (Defense Advanced Research Projects Agency). The PICASSO program aims to overcome fundamental physical limits preventing photonic integrated circuits from delivering large-scale computing advantages for artificial intelligence and other data-intensive workloads. It seeks innovative circuit-level design strategies to develop scalable photonic circuits with predictable system-level performance, focusing on continuous optical signal processing rather than incremental component improvements.
DPA26BZ06-DV023 is a Direct-to-Phase-II SBIR paying $700,000 over 18 months plus a $500,000 option. The physics demands 256x more transmit power than the systems that qualify you to compete, and DARPA will not accept modeling alone as proof. Here is the eligibility wall, the five engineering problems, and who can realistically win it before the October 21 close.
Read articleRelease 6's SBIR topics got the attention. Its three STTR topics — SHIELDER, fuel-flexible electric propulsion, and hypersonic wind tunnel noise diagnostics — are all Direct-to-Phase-II, all require a research institution to perform at least 30 percent of the work, and all close October 21, 2026. The feasibility gates are the real filter.
Read articleDPA26BZ06-DV026 offers $300,000 at Phase I or $1,800,000 as a single Direct-to-Phase-II tranche with no options. The deliverable is a simulated auction market that measures whether AI agents deceive, collude, or manipulate the humans they serve — measured entirely from the outside. Here is the 90% efficiency gate, the team composition most bidders will get wrong, and why this topic sits in DARPA's biology office.
Read article